| Invested through |
|
|---|---|
| Asset Classes | Listed equity & Corporate bonds |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | AZN LN |
| ISIN code | GB0009895292 |
| Industry group | Pharmaceuticals and biotechnology |
| Aligned with SDGs |
AstraZeneca researches, manufactures and sells pharmaceutical and medical products. Founded in 1999 through the merger of the Swedish Astra AB (formed in 1913, growing into the largest pharma company in Sweden) and the British Zeneca Group (formed in 1993 from the divestment of the British chemicals company ICI's pharma business), the company is headquartered in Cambridge, England, and employs around 83,500 people globally.
Investment rationale
AstraZeneca (AZ) is at the forefront of tackling non-communicable diseases (NCDs), which could account for 80% of deaths in low-income countries by 2040. AZ focuses on key therapeutic areas, including oncology, cardiovascular, renal, and metabolic diseases, as well as rare diseases. In cancer treatment, AZ pioneers precision medicines targeting hard-to-treat cancers like lung, breast, and pancreatic cancer. The company also leads in cardiovascular and diabetes treatments, addressing interconnected health risks. Its commitment to rare diseases was reinforced by acquiring Alexion in 2021.
Beyond innovation, AZ enhances global healthcare access through initiatives like Healthy Heart Africa and the Young Health Programme. Ranked third in the 2022 Access to Medicine Index, AZ drives equitable and affordable healthcare. Aligned with SDG 3: Good Health and Well-Being, AstraZeneca contributes to global well-being through cutting-edge treatments and expanded healthcare access.
In total, 100% of the revenues of the company is aligned with the Well-being transition. The contribution to the Well-being transition comes from 100% of revenues related to the impact objective Healthcare.